CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 71 enrolled
Drug / intervention
Revanesse Ultradevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02984878
NCT02984878N/ACompleted
CompareCT.gov

A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra (Retreatment)

Prollenium Medical Technologies Inc.·interventional·Posted Dec 7, 2016·Updated Dec 20, 2017

In Brief

A clinical study evaluating Revanesse Ultra for Nasolabial Fold Correction. Completed, enrolled 71 participants.

Detailed Summary

To compare improvement with retreatment for all subjects undergoing correction of nasolabial folds (NLFs) in the initial SYM2014-02 study, who were retreated with Revanesse Ultra at Visit 6/Week 24 and to determine the safety of repeat injections of Revanesse Ultra. The retreatment phase was optional.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasolabial Fold Correction
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 7, 2016
Enrollment StartNov 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.6 years ago

Interventions

Revanesse Ultradevice

Nasolabial Fold correction